Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

PHASE3CompletedINTERVENTIONAL

Enrollment

867

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions

Japanese Encephalitis

Interventions

BIOLOGICAL

IC51

IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28

BIOLOGICAL

JE-VAX

JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28

All Listed Sponsors

lead

Valneva Austria GmbH

INDUSTRY

NCT00604708 - Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 | Biotech Hunter | Biotech Hunter